REG - Redx Pharma plc - Change of Adviser

Redx PharmaAnnouncement

20/05/2020 07:00

RNS Number : 3816N
  
Redx Pharma plc
  
20 May 2020
  
 

20 May 2020
 
Redx Pharma plc
("Redx" or "the Company")
 
Change of Adviser
 
The Company announces that SPARK Advisory Partners Limited has been appointed as the Company's nominated adviser with immediate effect.
 
 




For further information, please contact:


 




 


 




Redx Pharma Plc 


T: +44 1625 469 918




Iain Ross, Chairman
Lisa Anson, Chief Executive


 




 


 




SPARK Advisory Partners Limited (Nominated Adviser)


 T: +44 203 368 3550




Matt Davis/Andrew Emmott


 




 


 




WG Partners LLP (Broker)


T: +44 20 3705 9330




Claes Spång/Chris Lee/David Wilson


 




 


 




FTI Consulting


T: +44 20 3727 1000




Simon Conway/Ciara Martin


 




 
 


 




 
About Redx Pharma Plc 
 
Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.
 
If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
APPSFDFDUESSEEI